References
- Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 48(Suppl 1):5–16. [accessed 2022 Mar 10]. doi:https://doi.org/10.1093/jac/48.suppl_1.5
- Bácskay I, Nemes D, Fenyvesi F, Váradi J, Vasvári G, Fehér P, Vecsernyés M, Ujhelyi Z. 2018. Role of cytotoxicity experiments in pharmaceutical development. In: Cytotoxicity. [place unknown]. doi:https://doi.org/10.5772/intechopen.72539
- Bar-Or Y. 1990. The effect of adhesion on survival and growth of microorganisms. Experientia. 46:823–826. doi:https://doi.org/10.1007/BF01935532
- Bhattacharya S, Sae-Tia S, Fries BC. 2020. Candidiasis and mechanisms of antifungal resistance. Antibiotics. 9:312–319. [accessed 2021 Apr 14]. doi:https://doi.org/10.3390/antibiotics9060312
- Bordallo-Cardona MÁ, Sánchez-Carrillo C, Muñoz P, Bouza E, Escribano P, Guinea J. 2019. Growth kinetics in Candida spp.: differences between species and potential impact on antifungal susceptibility testing as described by the EUCAST. Medical Mycology. 57:601–608. [accessed 2021 Apr 21]. doi:https://doi.org/10.1093/mmy/myy097
- Caeran Bueno D, Meinerz D, Allebrandt J, Waczuk E, dos Santos D, Mariano D, Rocha J. 2013. Cytotoxicity and genotoxicity evaluation of organochalcogens in human leucocytes: a comparative study between ebselen, diphenyl diselenide, and diphenyl ditelluride. Biomed Res Int. 2013: 537279. [accessed 2021 Nov 5]. doi:https://doi.org/10.1155/2013/537279
- Deray G. 2002. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 49 Suppl 1:37–41. [accessed 2022 Apr 29]. doi:https://doi.org/10.1093/jac/49.suppl_1.37
- El-Azizi M, Farag N, Khardori N. 2015. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model. Ann Clin Microbiol Antimicrob. 14. doi:https://doi.org/10.1186/s12941-015-0083-3
- Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, et al. 2014. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 58:2006–2012. [accessed 2021 Apr 26]. doi:https://doi.org/10.1128/AAC.02615-13
- Fanos V, Cataldi L. 2000. Amphotericin B-induced nephrotoxicity: a review. J Chemother. 12:463–470. [accessed 2022 Apr 29]. doi:https://doi.org/10.1179/joc.2000.12.6.463
- Feoktistova M, Geserick P, Leverkus M. 2016. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb Protoc. 2016:pdb.prot087379–346. doi:https://doi.org/10.1101/pdb.prot087379
- Finkel SE. 2006. Long-term survival during stationary phase: Evolution and the GASP phenotype. Nat Rev Microbiol. 4:113–120. [accessed 2021 Apr 21]. doi:https://doi.org/10.1038/nrmicro1340
- Gómez-Gaviria M, Mora-Montes HM. 2020. Current aspects in the biology, pathogeny, and treatment of candida krusei, a neglected fungal pathogen. Infect Drug Resist. 13:1673–1689. [accessed 2021 Apr 13]. doi:https://doi.org/10.2147/IDR.S247944
- Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. 1995. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis. 20:755–761. [accessed 2022 Apr 29]. doi:https://doi.org/10.1093/clinids/20.4.755
- Guinea J. 2014. Global trends in the distribution of Candida species causing candidemia. Clinical Microbiology and Infection [Internet]. 20:5–10. [accessed 2021 Apr 26]. doi:https://doi.org/10.1111/1469-0691.12539
- JL B, VR P, LS M, AM M, MR T, DA S, MO X. 2021. Ebselen and diphenyl diselenide against fungal pathogens: A systematic review. Med Mycol. 59:409–421. [accessed 2021 Oct 11]. doi:https://doi.org/10.1093/MMY/MYAA115
- Kennedy MJ. 1988. Adhesion and association mechanisms of Candida albicans. Curr Top Med Mycol. 2:73–169. doi:https://doi.org/10.1007/978-1-4612-3730-3_4.
- di Leo I, Messina F, Nascimento V, Nacca FG, Pietrella D, Lenardão EJ, Perin G, Sancineto L. 2019. Synthetic approaches to organoselenium derivatives with antimicrobial and anti-biofilm activity. MROC. 16:589–601. doi:https://doi.org/10.2174/1570193X16666181227111038
- Loreto ÉS, Nunes Mario DA, Santurio JM, Alves SH, Nogueira CW, Zeni G. 2011. In vitro antifungal evaluation and structure-activity relationship of diphenyl diselenide and synthetic analogues. Mycoses. 54:e572–e576. doi:https://doi.org/10.1111/j.1439-0507.2010.01994.x
- Mayer FL, Wilson D, Hube B. 2013. Candida albicans pathogenicity mechanisms. Virulence. 4:119–128. doi:https://doi.org/10.4161/viru.22913
- Mukherjee PK, Zhou G, Munyon R, Ghannoum MA. 2005. Candida biofilm: A well-designed protected environment. Med Mycol. 43:191–208. doi:https://doi.org/10.1080/13693780500107554
- Nogueira C, Rocha J. 2011. Toxicology and pharmacology of selenium: emphasis on synthetic organoselenium compounds. Arch Toxicol. 85:1313–1359. [accessed 2021 Sep 29]. doi:https://doi.org/10.1007/s00204-011-0720-3
- Nogueira CW, Barbosa N v, Rocha JBT. 2021. Toxicology and pharmacology of synthetic organoselenium compounds: an update. Arch Toxicol. 95:1179–1226. [accessed 2021 Apr 16]. doi:https://doi.org/10.1007/s00204-021-03003-5
- Nogueira CW, Zeni G, Rocha JBT. 2004. Organoselenium and organotellurium compounds: Toxicology and pharmacology. Chem Rev. 104:6255–6285. doi:https://doi.org/10.1021/cr0406559
- Orozco AS, Higginbotham LM, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS, Ghannoum MA, Filler SG. 1998. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 42:2645–2649. [accessed 2021 Apr 26]. doi:https://doi.org/10.1128/AAC.42.10.2645
- Paulmier C. 1986. Selenium reagents and intermediates in organic synthesis. In: Pergamon Press [Internet]. Vol. 4. p. 311–311463. http://doi.wiley.com/10.1002/ange.19881000236.
- Pereira R, Santos Fontenelle RO, Brito EHS, Morais SM. 2021. Biofilm of Candida albicans : Formation, regulation and resistance. J Appl Microbiol. 131:11–22. doi:https://doi.org/10.1111/jam.14949
- Querobino SM, de Faria NC, Vigato AA, da Silva BGM, Machado IP, Costa MS, Costa FN, de Araujo DR, Alberto-Silva C. 2019. Sodium alginate in oil-poloxamer organogels for intravaginal drug delivery: Influence on structural parameters, drug release mechanisms, cytotoxicity and in vitro antifungal activity. Mater Sci Eng C Mater Biol Appl. 99:1350–1361. doi:https://doi.org/10.1016/j.msec.2019.02.036
- Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. 2009. Our current understanding of fungal biofilms fungal biofilms Gordon ramage et al. Crit Rev Microbiol. 35:340–355. doi:https://doi.org/10.3109/10408410903241436
- Ramage G, Saville SP, Thomas DP, López-Ribot JL. 2005. Candida biofilms: An update. Eukaryot Cell. 4:633–638. doi:https://doi.org/10.1128/EC.4.4.633-638.2005
- Revie NM, Iyer KR, Robbins N, Cowen LE. 2018. Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol. 45:70–76. [accessed 2021 Apr 14]. doi:https://doi.org/10.1016/j.mib.2018.02.005
- Ricardo E, Miranda IM, Faria-Ramos I, Silva RM, Rodrigues AG, Pina VC. 2014. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. Antimicrob Agents Chemother. 58:4604–4611. [accessed 2021 Apr 18]. doi:https://doi.org/10.1128/AAC.02603-14
- Rosseti I, Junior P, Campos C, Rocha J, Costa M. 2014. Biofilm formation by Candida albicans is inhibited by 4,4-dichloro diphenyl diselenide (pCl-PhSe)2. Curr Drug Discov Technol. 11:234–238. doi:https://doi.org/10.2174/1570163811666140924121758
- Rosseti IB, Rocha JBT, Costa MS. 2015. Diphenyl diselenide (PhSe)2 inhibits biofilm formation by Candida albicans, increasing both ROS production and membrane permeability. J Trace Elem Med Biol. 29:289–295. doi:https://doi.org/10.1016/j.jtemb.2014.08.001
- Rosseti IB, Wagner C, Fachinetto R, Taube Junior P, Costa MS. 2011. Candida albicans growth and germ tube formation can be inhibited by simple diphenyl diselenides [(PhSe)2, (MeOPhSe)2, (p-Cl-PhSe)2, (F3CPhSe)2] and diphenyl ditelluride. Mycoses. 54:506–513. doi:https://doi.org/10.1111/j.1439-0507.2010.01888.x
- Samaranayake YH, Samaranayake LP. 1994. Candida krusei: Biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol. 41:295–310. [accessed 2021 Apr 26]. doi:https://doi.org/10.1099/00222615-41-5-295
- Santi C, Scimmi C, Sancineto L. 2021. Ebselen and analogues: pharmacological properties and synthetic strategies for their preparation. Molecules. 26:4230. [accessed 2021 Sep 29 . doi:https://doi.org/10.3390/molecules26144230
- Sardi JCO, Almeida AMF, Mendes Giannini MJS. 2011. New antimicrobial therapies used against fungi present in subgingival sites-a brief review. Arch Oral Biol. 56:951–959. doi:https://doi.org/10.1016/j.archoralbio.2011.03.007
- Sardi JDCO, Pitangui NDS, Rodríguez-Arellanes G, Taylor ML, Fusco-Almeida AM, Mendes-Giannini MJS. 2014. Highlights in pathogenic fungal biofilms. Rev Iberoam Micol. 31:22–29. doi:https://doi.org/10.1016/j.riam.2013.09.014
- Segal E, Sandovsky-Losica H. 1995. Adhesion and interaction of Candida albicans with mammalian tissues in vitro and in vivo. Methods Enzymol. 253:439–452. doi:https://doi.org/10.1016/S0076-6879(95)53038-X.
- Seneviratne CJ, Jin L, Samaranayake LP. 2008. Biofilm lifestyle of Candida: A mini review. Oral Dis. 14:582–590. doi:https://doi.org/10.1111/j.1601-0825.2007.01424.x
- Sieniawska E, Świątek Ł, Wota M, Rajtar B, Polz-Dacewicz M. 2019. Microemulsions of essentials oils - Increase of solubility and antioxidant activity or cytotoxicity? Food Chem Toxicol. 129:115–124. [accessed 2021 Apr 22]. doi:https://doi.org/10.1016/j.fct.2019.04.038
- da Silva BM, Braga MT, da Silva Passos JC, Carvalho ML, Rosseti IB, de Amorim LMM, da Rocha JBT, Alberto-Silva C, Costa MS. 2021. 2021. (PhSe)2 and (pCl-PhSe)2 organochalcogen compounds inhibit Candida albicans adhesion to human endocervical (HeLa) cells and show anti-biofilm activities. Biofouling. 37:235–245. [accessed Apr 10]. doi:https://doi.org/10.1080/08927014.2021.1897110
- Singh DK, Tóth R, Gácser A. 2020. Mechanisms of pathogenic Candida species to evade the host complement attack. Front Cell Infect Microbiol. 10:94. [accessed 2021 Apr 13]. doi:https://doi.org/10.3389/fcimb.2020.00094
- Stevenson RE, Jong SC. 1992. Application of good laboratory practice (GLP) to culture collections of microbial and cell cultures. World J Microbiol Biotechnol. 8:229–235. [accessed 2021 May 6]. doi:https://doi.org/10.1007/BF01201869
- Tobudic S, Kratzer C, Lassnigg A, Presterl E. 2012. Antifungal susceptibility of Candida albicans in biofilms. Mycoses. 55:199–204. doi:https://doi.org/10.1111/j.1439-0507.2011.02076.x
- Tsui C, Kong EF, Jabra-Rizk MA. 2016. Pathogenesis of Candida albicans biofilm. Pathog Dis. 74:ftw018. doi:https://doi.org/10.1093/femspd/ftw018
- Vermeersch L, Perez-Samper G, Cerulus B, Jariani A, Gallone B, Voordeckers K, Steensels J, Verstrepen KJ. 2019. On the duration of the microbial lag phase. Curr Genet. 65:721–727. [accessed 2021 Apr 21]. doi:https://doi.org/10.1007/s00294-019-00938-2
- Wall G, Lopez-Ribot JL. 2020. Screening repurposing libraries for identification of drugs with novel antifungal activity. Antimicrob Agents Chemother. 64. [accessed 2021 Apr 16]. doi:https://doi.org/10.1128/AAC.00924-20
- Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. 2016. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida Species. Front Microbiol. 7(JAN):2173. [accessed 2021 Apr 18]. doi:https://doi.org/10.3389/fmicb.2016.02173
- Xia J, Qian F, Xu W, Zhang Z, Wei X. 2017. In vitro inhibitory effects of farnesol and interactions between farnesol and antifungals against biofilms of Candida albicans resistant strains. Biofouling. 33:283–293. doi:https://doi.org/10.1080/08927014.2017.1295304